Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04391920 · ClinicalTrials.gov registry record
Registry of CytoSorb Therapy in COVID-19 ICU Patients
A clinical trial, sponsored by CytoSorbents.
- Completed
- Registry status
- 138
- Enrollment target
NCT04391920 is a clinical trial that has completed, run by CytoSorbents. The registered enrollment target is 138 participants.
The verdict
NCT04391920 has completed, sponsored by CytoSorbents.
- COMPLETED
- Registry status
- 138 participants
- Enrollment target
Study Summary
The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption provides clinical benefit to COVID-19 ICU patients.
Interventions
- DEVICE CytoSorb 300 mL device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2020-08-28 |
| Est. Completion | 2022-01-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04391920
The ClinicalTrials.gov registry entry for NCT04391920 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoSorbents, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CytoSorb 300 mL device is the first listed.
NCT04391920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04391920 about?
NCT04391920 is a clinical study titled "Registry of CytoSorb Therapy in COVID-19 ICU Patients". The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption prov...
What is the current status of trial NCT04391920?
This trial is currently completed. The enrollment target is 138 participants. The study started on 2020-08-28. Estimated completion is 2022-01-20.
What interventions are being tested in trial NCT04391920?
The interventions under investigation include: CytoSorb 300 mL device (DEVICE).
Who is sponsoring clinical trial NCT04391920?
This trial is sponsored by CytoSorbents, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.